isoniazid has been researched along with Rheumatism in 25 studies
Hydra: A genus of freshwater polyps in the family Hydridae, order Hydroida, class HYDROZOA. They are of special interest because of their complex organization and because their adult organization corresponds roughly to the gastrula of higher animals.
hydrazide : Compounds derived from oxoacids RkE(=O)l(OH)m (l =/= 0) by replacing -OH by -NRNR2 (R groups are commonly H). (IUPAC).
| Excerpt | Relevance | Reference |
|---|---|---|
| "In this study, we investigated the safety and toxicity of isoniazid (INH) intervention therapy to the patients with latent tuberculosis who were given tumor necrosis factor alpha (TNFalpha) for the treatment of their rheumatologic diseases." | 9.12 | Isoniazid intervention for latent tuberculosis among 86 patients with rheumatologic disease administered with anti-TNFalpha. ( Hanta, I; Kocabas, A; Kuleci, S; Ozbek, S; Sert, M, 2007) |
| "To investigate the incidence of tuberculosis (TB) in patients with rheumatic diseases receiving high-dose glucocorticoids and to evaluate the preventive effect of isoniazid (INH)." | 7.96 | Risk-benefit analysis of isoniazid monotherapy to prevent tuberculosis in patients with rheumatic diseases exposed to prolonged, high-dose glucocorticoids. ( Curtis, JR; Lee, EB; Lee, H; Lee, JK; Park, JW; Song, YW, 2020) |
| "In this study, we investigated the safety and toxicity of isoniazid (INH) intervention therapy to the patients with latent tuberculosis who were given tumor necrosis factor alpha (TNFalpha) for the treatment of their rheumatologic diseases." | 5.12 | Isoniazid intervention for latent tuberculosis among 86 patients with rheumatologic disease administered with anti-TNFalpha. ( Hanta, I; Kocabas, A; Kuleci, S; Ozbek, S; Sert, M, 2007) |
| "To investigate the incidence of tuberculosis (TB) in patients with rheumatic diseases receiving high-dose glucocorticoids and to evaluate the preventive effect of isoniazid (INH)." | 3.96 | Risk-benefit analysis of isoniazid monotherapy to prevent tuberculosis in patients with rheumatic diseases exposed to prolonged, high-dose glucocorticoids. ( Curtis, JR; Lee, EB; Lee, H; Lee, JK; Park, JW; Song, YW, 2020) |
| " For treatment of latent tuberculosis infection (LTBI) overall, 49% of the respondents would refer management to infectious disease specialist or the health department, 37% would initiate isoniazid for 9 or 12 months, and 14% would use isoniazid for 6 months." | 3.85 | Screening and Treatment of Latent Tuberculosis Among Patients Receiving Biologic Agents: A National and International Survey of Rheumatologists. ( Carbone, L; Garcia-Rosell, M; Pattanaik, D; Raza, SH; Tran, NQ, 2017) |
| " Steroid dosage varied according to diagnosis and severity." | 2.69 | Is a purified protein derivative skin test and subsequent antituberculous chemoprophylaxis really necessary in systemic rheumatic disease patients receiving corticosteroids? ( Andonopoulos, AP; Bounas, A; Karokis, D; Safridi, C, 1998) |
| "Isoniazid was prescribed if any one test was positive." | 1.56 | Comparison of single and dual latent tuberculosis screening strategies before biologic and targeted therapy in patients with rheumatic diseases: a retrospective cohort study. ( Lao, V; Luk, L; Pang, S; So, H; Tang, I; Wong, V; Yip, R, 2020) |
| "Data from regular monitoring for latent tuberculosis infection [LTBI] during biologic treatment are lacking." | 1.48 | A Prospective Study to Monitor for Tuberculosis During Anti-tumour Necrosis Factor Therapy in Patients With Inflammatory Bowel Disease and Immune-mediated Inflammatory Diseases. ( Chen, M; Hung, E; Ip, M; Lee, CK; Lui, G; Ng, SC; Tam, LS; Tang, W; Wong, SHV; Wu, JC, 2018) |
| " Although the use of INH therapy in combination with DMARDs and/or biologics was generally well tolerated, the rate of LFT abnormalities was higher when patients were exposed to INH, and significant abnormalities were more frequent than reported in the INH literature." | 1.40 | Increased incidence of liver enzymes abnormalities in patients treated with isoniazid in combination with disease modifying and/or biologic agents. ( Arino-Torregrosa, M; Bourré-Tessier, J; Choquette, D, 2014) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 9 (36.00) | 18.7374 |
| 1990's | 1 (4.00) | 18.2507 |
| 2000's | 3 (12.00) | 29.6817 |
| 2010's | 10 (40.00) | 24.3611 |
| 2020's | 2 (8.00) | 2.80 |
| Authors | Studies |
|---|---|
| Tang, I | 1 |
| So, H | 1 |
| Luk, L | 1 |
| Wong, V | 1 |
| Pang, S | 1 |
| Lao, V | 1 |
| Yip, R | 1 |
| Park, JW | 1 |
| Curtis, JR | 1 |
| Lee, H | 1 |
| Lee, JK | 1 |
| Song, YW | 1 |
| Lee, EB | 1 |
| Lee, CK | 1 |
| Wong, SHV | 1 |
| Lui, G | 1 |
| Tang, W | 1 |
| Tam, LS | 1 |
| Ip, M | 1 |
| Hung, E | 1 |
| Chen, M | 1 |
| Wu, JC | 1 |
| Ng, SC | 1 |
| He, D | 1 |
| Bai, F | 1 |
| Zhang, S | 1 |
| Jiang, T | 1 |
| Shen, J | 1 |
| Zhu, Q | 1 |
| Yue, T | 1 |
| Shao, L | 1 |
| Gao, Y | 1 |
| Feng, Y | 1 |
| Weng, X | 1 |
| Zou, H | 1 |
| Zhang, Y | 1 |
| Zhang, W | 1 |
| Kurt, OK | 1 |
| Kurt, B | 1 |
| Talay, F | 1 |
| Tug, T | 1 |
| Soy, M | 1 |
| Bes, C | 1 |
| Hayran, M | 1 |
| Valls, V | 1 |
| Ena, J | 1 |
| Bourré-Tessier, J | 1 |
| Arino-Torregrosa, M | 1 |
| Choquette, D | 1 |
| Atikan, BY | 1 |
| Cavusoglu, C | 1 |
| Dortkardesler, M | 1 |
| Sozeri, B | 1 |
| Tran, NQ | 1 |
| Garcia-Rosell, M | 1 |
| Pattanaik, D | 1 |
| Raza, SH | 1 |
| Carbone, L | 1 |
| Ekochin, LH | 1 |
| Manadan, AM | 1 |
| Aggarwal, R | 1 |
| Sequeira, W | 1 |
| Block, JA | 1 |
| Bray, MG | 1 |
| Poulain, C | 1 |
| Dougados, M | 1 |
| Gossec, L | 1 |
| Haroon, M | 1 |
| Martin, U | 1 |
| Devlin, J | 1 |
| Nobre, CA | 1 |
| Callado, MR | 1 |
| Lima, JR | 1 |
| Gomes, KW | 1 |
| Martiniano, GV | 1 |
| Vieira, WP | 1 |
| WALCZAK, H | 1 |
| Hanta, I | 1 |
| Ozbek, S | 1 |
| Kuleci, S | 1 |
| Sert, M | 1 |
| Kocabas, A | 1 |
| Falagas, ME | 1 |
| Voidonikola, PT | 1 |
| Angelousi, AG | 1 |
| Andonopoulos, AP | 1 |
| Safridi, C | 1 |
| Karokis, D | 1 |
| Bounas, A | 1 |
| Duroux, P | 1 |
| Banerjee, HK | 1 |
| Goldman, AL | 1 |
| Braman, SS | 1 |
| Anastasatu, C | 2 |
| Stoia, I | 1 |
| Kaufman, S | 1 |
| Ghenoiu, O | 1 |
| Iancovici, O | 2 |
| Thibault, H | 1 |
| Ritzel, R | 1 |
| Vetter, GW | 1 |
| Kauffmann, S | 1 |
| Good, AE | 1 |
1 review available for isoniazid and Rheumatism
| Article | Year |
|---|---|
Tuberculosis in patients with systemic rheumatic or pulmonary diseases treated with glucocorticosteroids and the preventive role of isoniazid: a review of the available evidence.
Topics: Adult; Aged; Antitubercular Agents; Case-Control Studies; Cohort Studies; Female; Humans; Incidence; | 2007 |
3 trials available for isoniazid and Rheumatism
| Article | Year |
|---|---|
Short-course treatment of latent tuberculosis infection in patients with rheumatic conditions proposed for anti-TNF therapy.
Topics: Adult; Aged; Antirheumatic Agents; Antitubercular Agents; Drug Therapy, Combination; Female; Humans; | 2015 |
Isoniazid intervention for latent tuberculosis among 86 patients with rheumatologic disease administered with anti-TNFalpha.
Topics: Adult; Alanine Transaminase; Antitubercular Agents; Arthritis, Psoriatic; Arthritis, Rheumatoid; Asp | 2007 |
Is a purified protein derivative skin test and subsequent antituberculous chemoprophylaxis really necessary in systemic rheumatic disease patients receiving corticosteroids?
Topics: Adrenal Cortex Hormones; Adult; Aged; Aged, 80 and over; Antitubercular Agents; Confidence Intervals | 1998 |
21 other studies available for isoniazid and Rheumatism
| Article | Year |
|---|---|
Comparison of single and dual latent tuberculosis screening strategies before biologic and targeted therapy in patients with rheumatic diseases: a retrospective cohort study.
Topics: Adult; Aged; Biological Products; Female; Humans; Incidence; Infliximab; Interferon-gamma Release Te | 2020 |
Risk-benefit analysis of isoniazid monotherapy to prevent tuberculosis in patients with rheumatic diseases exposed to prolonged, high-dose glucocorticoids.
Topics: Adult; Antitubercular Agents; Female; Glucocorticoids; Humans; Isoniazid; Male; Middle Aged; Prognos | 2020 |
A Prospective Study to Monitor for Tuberculosis During Anti-tumour Necrosis Factor Therapy in Patients With Inflammatory Bowel Disease and Immune-mediated Inflammatory Diseases.
Topics: Adult; Antirheumatic Agents; Antitubercular Agents; Biological Therapy; Female; Gastrointestinal Age | 2018 |
High incidence of tuberculosis infection in rheumatic diseases and impact for chemoprophylactic prevention of tuberculosis activation during biologics therapy.
Topics: Adolescent; Adult; Aged; Antitubercular Agents; Biological Products; Chemoprevention; Female; Humans | 2013 |
Intermediate to long-term follow-up results of INH chemoprophylaxis prior to anti-TNF-alpha therapy in a high-risk area for tuberculosis.
Topics: Adolescent; Adult; Aged; Antirheumatic Agents; Antitubercular Agents; Chemoprevention; Drug-Related | 2013 |
Increased incidence of liver enzymes abnormalities in patients treated with isoniazid in combination with disease modifying and/or biologic agents.
Topics: Adult; Antirheumatic Agents; Antitubercular Agents; Biological Products; Chemical and Drug Induced L | 2014 |
Assessment of tuberculosis infection during treatment with biologic agents in a BCG-vaccinated pediatric population.
Topics: Adolescent; Antitubercular Agents; BCG Vaccine; Child; Child, Preschool; Female; Follow-Up Studies; | 2016 |
Screening and Treatment of Latent Tuberculosis Among Patients Receiving Biologic Agents: A National and International Survey of Rheumatologists.
Topics: Antitubercular Agents; Attitude of Health Personnel; Biological Products; Female; Humans; Interferon | 2017 |
Absence of transaminase elevation during concomitant methotrexate and isoniazid therapy.
Topics: Adult; Aged; Antirheumatic Agents; Antitubercular Agents; Cohort Studies; Female; Humans; Isoniazid; | 2009 |
Frequency and tolerance of antituberculosis treatment according to national guidelines for prevention of risk of tuberculosis due to tumor necrosis factor blocker treatment.
Topics: Adult; Antitubercular Agents; Chemical and Drug Induced Liver Injury; Databases, Factual; Female; Hu | 2010 |
High incidence of intolerance to tuberculosis chemoprophylaxis.
Topics: Adult; Aged; Antirheumatic Agents; Antitubercular Agents; Chemical and Drug Induced Liver Injury; Ch | 2012 |
Tuberculosis infection in rheumatic patients with infliximab therapy: experience with 157 patients.
Topics: Adult; Antibodies, Monoclonal; Antirheumatic Agents; Antitubercular Agents; Arthritis, Psoriatic; Ar | 2012 |
[ON THE TREATMENT OF DIFFERENT TYPES OF RHEUMATIC DISEASES IN PULMONARY TUBERCULOSIS AND LUNG TUMORS].
Topics: Agranulocytosis; Aminosalicylic Acid; Aminosalicylic Acids; Isoniazid; Leukopenia; Lung; Lung Neopla | 1964 |
[Surveillance and complications of antituberculosis chemotherapy].
Topics: Antitubercular Agents; Chemical and Drug Induced Liver Injury; Drug Eruptions; Drug Hypersensitivity | 1979 |
Rheumatoid syndrome during antitubercular therapy.
Topics: Adolescent; Adult; Female; Humans; Isoniazid; Male; Middle Aged; Pyridoxine; Rheumatic Diseases | 1977 |
Isoniazid: a review with emphasis on adverse effects.
Topics: Anemia, Hemolytic; Chemical and Drug Induced Liver Injury; Desensitization, Immunologic; Drug Hypers | 1972 |
[Rheumatic diseases caused by antitubercular drugs].
Topics: Adult; Aged; Aminosalicylic Acids; Antitubercular Agents; Arthritis, Rheumatoid; Cycloserine; Dupuyt | 1972 |
[Uncommon reactions to isoniazid].
Topics: Central Nervous System; Chemical and Drug Induced Liver Injury; Drug Hypersensitivity; Drug Interact | 1973 |
[Experience with Delta-Tomanol, a new antirheumatic combination preparation].
Topics: Drug Synergism; Humans; Isoniazid; Phenylbutazone; Prednisolone; Rheumatic Diseases | 1968 |
[Manifestations of a rheumatic type caused by antituberculosis chemotherapy].
Topics: Acrodynia; Aged; Antitubercular Agents; Arthritis, Rheumatoid; Cycloserine; Ethionamide; Female; Hum | 1969 |
Rheumatism and chemotherapy of tuberculosis.
Topics: Humans; Isoniazid; Rheumatic Diseases; Tuberculosis | 1970 |